{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:41:12Z","timestamp":1787956872535,"version":"build-2784847793"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amsterdam UMC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      We aimed to investigate associations between tau pathology and relative cerebral blood flow (rCBF), and their relationship with cognition in Alzheimer\u2019s disease (AD), by using a single dynamic [\n                      <jats:sup>18<\/jats:sup>\n                      F]flortaucipir positron emission tomography (PET) scan.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Seventy-one subjects with AD (66\u2009\u00b1\u20098\u00a0years, mini-mental state examination (MMSE) 23\u2009\u00b1\u20094) underwent a dynamic 130-min [\n                      <jats:sup>18<\/jats:sup>\n                      F]flortaucipir PET scan. Cognitive assessment consisted of composite scores of four cognitive domains. For tau pathology and rCBF, receptor parametric mapping (cerebellar gray matter reference region) was used to create uncorrected and partial volume-corrected parametric images of non-displaceable binding potential (BP\n                      <jats:sub>ND<\/jats:sub>\n                      ) and\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sub>\n                        <jats:italic>1<\/jats:italic>\n                      <\/jats:sub>\n                      , respectively. (Voxel-wise) linear regressions were used to investigate associations between BP\n                      <jats:sub>ND<\/jats:sub>\n                      and\/or\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sub>\n                        <jats:italic>1<\/jats:italic>\n                      <\/jats:sub>\n                      and cognition\n                      <jats:sub>.<\/jats:sub>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Higher [\n                      <jats:sup>18<\/jats:sup>\n                      F]flortaucipir BP\n                      <jats:sub>ND<\/jats:sub>\n                      was associated with lower\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sub>\n                        <jats:italic>1<\/jats:italic>\n                      <\/jats:sub>\n                      in the lateral temporal, parietal and occipital regions. Higher medial temporal BP\n                      <jats:sub>ND<\/jats:sub>\n                      was associated with worse memory, and higher lateral temporal BP\n                      <jats:sub>ND<\/jats:sub>\n                      with worse executive functioning and language. Higher parietal BP\n                      <jats:sub>ND<\/jats:sub>\n                      was associated with worse executive functioning, language and attention, and higher occipital BP\n                      <jats:sub>ND<\/jats:sub>\n                      with lower cognitive scores across all domains. Higher frontal BP\n                      <jats:sub>ND<\/jats:sub>\n                      was associated with worse executive function and attention. For [\n                      <jats:sup>18<\/jats:sup>\n                      F]flortaucipir\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sub>\n                        <jats:italic>1<\/jats:italic>\n                      <\/jats:sub>\n                      , lower values in the lateral temporal and parietal ROIs were associated with worse executive functioning, language and attention, and lower occipital\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sub>\n                        <jats:italic>1<\/jats:italic>\n                      <\/jats:sub>\n                      with lower language and attention scores. When [\n                      <jats:sup>18<\/jats:sup>\n                      F]flortaucipir BP\n                      <jats:sub>ND<\/jats:sub>\n                      and\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sub>\n                        <jats:italic>1<\/jats:italic>\n                      <\/jats:sub>\n                      were modelled simultaneously, associations between lower\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sub>\n                        <jats:italic>1<\/jats:italic>\n                      <\/jats:sub>\n                      in the lateral temporal ROI\u00a0 and worse attention remained, as well as for lower parietal\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sub>\n                        <jats:italic>1<\/jats:italic>\n                      <\/jats:sub>\n                      and worse executive functioning and attention.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tau pathology was associated with locally reduced rCBF. Tau pathology and low rCBF were both independently associated with worse cognitive performance. For tau pathology, these associations spanned widespread neocortex, while for rCBF, independent associations were restricted to lateral temporal and parietal regions and the executive functioning and attention domains. These findings indicate that each biomarker may independently contribute to cognitive impairment in AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-020-04831-w","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T02:02:30Z","timestamp":1590544950000},"page":"3165-3175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-146X","authenticated-orcid":false,"given":"Denise","family":"Visser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma E.","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander C. J.","family":"Verfaillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma M.","family":"Coomans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Timmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayel","family":"Tuncel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhan","family":"Reimand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert D.","family":"Windhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart N. M.","family":"van Berckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"4831_CR1","doi-asserted-by":"publisher","unstructured":"Sch\u00f6ll M, Maass A, Mattsson N, Ashton N, Blennow K, Zetterberg H, et al. Biomarkers for tau pathology. Mol Cell Neurosci 2019;97:18-33. https:\/\/doi.org\/10.1016\/j.mcn.2018.12.001","DOI":"10.1016\/j.mcn.2018.12.001"},{"key":"4831_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/alzrt195","volume":"5","author":"R Ossenkoppele","year":"2013","unstructured":"Ossenkoppele R, Prins N, Berckel B. Amyloid imaging in clinical trials. Alzheimers Res Ther. 2013;5:36. https:\/\/doi.org\/10.1186\/alzrt195.","journal-title":"Alzheimers Res Ther"},{"key":"4831_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.neuroimage.2008.04.251","volume":"42","author":"M Yaqub","year":"2008","unstructured":"Yaqub M, Tolboom N, Boellaard R, van Berckel BN, van Tilburg EW, Luurtsema G, et al. Simplified parametric methods for [11C] PIB studies. Neuroimage. 2008;42:76\u201386.","journal-title":"Neuroimage."},{"key":"4831_CR4","doi-asserted-by":"publisher","first-page":"e0211000","DOI":"10.1371\/journal.pone.0211000","volume":"14","author":"DE Peretti","year":"2019","unstructured":"Peretti DE, Garc\u00eda DV, Reesink FE, van der Goot T, De Deyn PP, de Jong BM, et al. Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer\u2019s disease PET studies. PLoS One. 2019;14:e0211000.","journal-title":"PLoS One"},{"key":"4831_CR5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1177\/0271678X16645593","volume":"37","author":"E Rodriguez-Vieitez","year":"2017","unstructured":"Rodriguez-Vieitez E, Leuzy A, Chiotis K, Saint-Aubert L, Wall A, Nordberg A. Comparability of [18F] THK5317 and [11C] PIB blood flow proxy images with [18F] FDG positron emission tomography in Alzheimer\u2019s disease. J Cereb Blood Flow Metab. 2017;37:740\u20139.","journal-title":"J Cereb Blood Flow Metab"},{"key":"4831_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13550-019-0528-3","volume":"9","author":"DE Peretti","year":"2019","unstructured":"Peretti DE, Garc\u00eda DV, Reesink FE, Doorduin J, de Jong BM, De Deyn PP, et al. Diagnostic performance of regional cerebral blood flow images derived from dynamic PIB scans in Alzheimer\u2019s disease. EJNMMI Res. 2019;9:59.","journal-title":"EJNMMI Res"},{"key":"4831_CR7","first-page":"669","volume":"10","author":"N Joseph-Mathurin","year":"2018","unstructured":"Joseph-Mathurin N, Su Y, Blazey TM, Jasielec M, Vlassenko A, Friedrichsen K, et al. Utility of perfusion PET measures to assess neuronal injury in Alzheimer\u2019s disease. Alzheimers Dement. 2018;10:669\u201377.","journal-title":"Alzheimers Dement"},{"key":"4831_CR8","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.114.152405","volume":"56","author":"YJ Chen","year":"2015","unstructured":"Chen YJ, Rosario BL, Mowrey W, Laymon CM, Lu X, Lopez OL, et al. Relative 11C-PiB delivery as a proxy of relative CBF: quantitative evaluation using single-session 15O-water and 11C-PiB PET. J Nucl Med. 2015;56:1199\u2013205.","journal-title":"J Nucl Med"},{"key":"4831_CR9","doi-asserted-by":"publisher","unstructured":"Ottoy J, Verhaeghe J, Niemantsverdriet E, De Roeck E, Wyffels L, Ceyssens S, et al. 18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies of cerebral blood flow in Alzheimer\u2019s disease: validation against 15O-H2O PET. Alzheimers Dement. 2019. https:\/\/doi.org\/10.1016\/j.jalz.2019.05.010.","DOI":"10.1016\/j.jalz.2019.05.010."},{"key":"4831_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79:110\u20139.","journal-title":"Ann Neurol"},{"key":"4831_CR11","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139:1551\u201367.","journal-title":"Brain."},{"key":"4831_CR12","first-page":"748","volume":"140","author":"MJ Pontecorvo","year":"2017","unstructured":"Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140:748\u201363.","journal-title":"Brain."},{"key":"4831_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jalz.2016.08.013","volume":"13","author":"AE Leeuwis","year":"2017","unstructured":"Leeuwis AE, Benedictus MR, Kuijer JP, Binnewijzend MA, Hooghiemstra AM, Verfaillie SC, et al. Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer\u2019s disease. Alzheimers Dement. 2017;13:531\u201340.","journal-title":"Alzheimers Dement"},{"key":"4831_CR14","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"WM Van Der Flier","year":"2018","unstructured":"Van Der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimers Dis. 2018;62:1091\u2013111.","journal-title":"J Alzheimers Dis"},{"key":"4831_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"4831_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139.","journal-title":"Alzheimers Dement"},{"key":"4831_CR17","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1373\/clinchem.2017.281055","volume":"64","author":"BM Tijms","year":"2018","unstructured":"Tijms BM, Willemse EA, Zwan MD, Mulder SD, Visser PJ, van Berckel BN, et al. Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-\u03b2 1\u201342 analysis results. Clin Chem. 2018;64:576\u201385.","journal-title":"Clin Chem"},{"key":"4831_CR18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"4831_CR19","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s11307-017-1080-z","volume":"19","author":"SS Golla","year":"2017","unstructured":"Golla SS, Timmers T, Ossenkoppele R, Groot C, Verfaillie S, Scheltens P, et al. Quantification of tau load using [18 F] AV1451 PET. Mol Imaging Biol. 2017;19:963\u201371.","journal-title":"Mol Imaging Biol"},{"key":"4831_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/hbm.10123","volume":"19","author":"A Hammers","year":"2003","unstructured":"Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224\u201347.","journal-title":"Hum Brain Mapp"},{"key":"4831_CR21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1006\/nimg.1997.0303","volume":"6","author":"RN Gunn","year":"1997","unstructured":"Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:279\u201387.","journal-title":"Neuroimage."},{"key":"4831_CR22","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2967\/jnumed.116.188029","volume":"58","author":"AA Lammertsma","year":"2017","unstructured":"Lammertsma AA. Forward to the past: the case for quantitative PET imaging. J Nucl Med. 2017;58:1019\u201324.","journal-title":"J Nucl Med"},{"key":"4831_CR23","doi-asserted-by":"publisher","unstructured":"Golla SS, Wolters EE, Timmers T, Ossenkoppele R, van der Weijden CW, Scheltens P, et al. Parametric methods for [18F] flortaucipir PET. J Cereb Blood Flow Metab. 2019;0271678X18820765. 40(2):365-373. https:\/\/doi.org\/10.1177\/0271678X18820765","DOI":"10.1177\/0271678X18820765"},{"key":"4831_CR24","doi-asserted-by":"publisher","unstructured":"Timmers T, Ossenkoppele R, Visser D, Tuncel H, Wolters E, Verfaillie SCJ, et al. Test-retest repeatability of [18F]Flortaucipir PET in Alzheimer\u2019s disease and cognitively normal individuals. J Cereb Blood Flow Metab. 2019; in press.https:\/\/doi.org\/10.1177\/0271678X19879226","DOI":"10.1177\/0271678X19879226"},{"key":"4831_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13550-017-0284-1","volume":"7","author":"SS Golla","year":"2017","unstructured":"Golla SS, Lubberink M, van Berckel BN, Lammertsma AA, Boellaard R. Partial volume correction of brain PET studies using iterative deconvolution in combination with HYPR denoising. EJNMMI Res. 2017;7:36.","journal-title":"EJNMMI Res"},{"key":"4831_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13550-019-0483-z","volume":"9","author":"M Cysouw","year":"2019","unstructured":"Cysouw M, Golla S, Frings V, Smit E, Hoekstra O, Kramer G, et al. Partial-volume correction in dynamic PET-CT: effect on tumor kinetic parameter estimation and validation of simplified metrics. EJNMMI Res. 2019;9:12.","journal-title":"EJNMMI Res"},{"key":"4831_CR27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging. Am J Roentgenol. 1987;149:351\u20136.","journal-title":"Am J Roentgenol"},{"key":"4831_CR28","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1212\/WNL.0000000000004802","volume":"90","author":"C Groot","year":"2018","unstructured":"Groot C, van Loenhoud AC, Barkhof F, van Berckel BN, Koene T, Teunissen CC, et al. Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology. 2018;90:e149\u2013e56.","journal-title":"Neurology."},{"key":"4831_CR29","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/brain\/awx243","volume":"140","author":"A Bejanin","year":"2017","unstructured":"Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer\u2019s disease. Brain. 2017;140:3286\u2013300.","journal-title":"Brain."},{"key":"4831_CR30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nrn.2017.48","volume":"18","author":"K Kisler","year":"2017","unstructured":"Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18:419. https:\/\/doi.org\/10.1038\/nrn.2017.48.","journal-title":"Nat Rev Neurosci"},{"key":"4831_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13195-019-0518-8","volume":"11","author":"LA Digma","year":"2019","unstructured":"Digma LA, Madsen JR, Reas ET, Dale AM, Brewer JB, Banks SJ. Tau and atrophy: domain-specific relationships with cognition. Alzheimers Res Ther. 2019;11:65.","journal-title":"Alzheimers Res Ther"},{"key":"4831_CR32","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","volume":"32","author":"SM Landau","year":"2011","unstructured":"Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207\u201318.","journal-title":"Neurobiol Aging"},{"key":"4831_CR33","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3233\/JAD-160316","volume":"55","author":"J Dronse","year":"2017","unstructured":"Dronse J, Fliessbach K, Bischof GN, von Reutern B, Faber J, Hammes J, et al. In vivo patterns of tau pathology, amyloid-\u03b2 burden, and neuronal dysfunction in clinical variants of Alzheimer\u2019s disease. J Alzheimers Dis. 2017;55:465\u201371.","journal-title":"J Alzheimers Dis"},{"key":"4831_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207\u201316.","journal-title":"Lancet Neurol"},{"key":"4831_CR35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1042\/CS20100094","volume":"119","author":"R Altman","year":"2010","unstructured":"Altman R, Rutledge JC. The vascular contribution to Alzheimer\u2019s disease. Clin Sci. 2010;119:407\u201321.","journal-title":"Clin Sci"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04831-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-020-04831-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-04831-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T19:27:40Z","timestamp":1622057260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-020-04831-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":35,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4831"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-04831-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"23 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Visser, Wolters, Verfaillie, Coomans, Timmers, Tuncel, Reimand, Boellaard, Windhorst and Ossenkoppele declare that they have no conflict of interest.Van der Flier received grant support from ZonMW, NWO, EU-FP7, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Stichting Dioraphte, Gieskes-Strijbis Fonds, Boehringer Ingelheim, Piramal Neuroimaging, Roche BV, Janssen Stellar, Combinostics. All funding is paid to the institution. WvdF holds the Pasman chair.Van Berckel received research support from ZON-MW, AVID radiopharmaceuticals, CTMM and Janssen Pharmaceuticals. He is a trainer for Piramal and GE. He receives no personal honoraria.Scheltens received grant support (to the institution) from GE Healthcare, Danone Research, Piramal and MERCK. In the past 2\u00a0years, he has received consultancy\/speaker fees from Lilly, GE Healthcare, Novartis, Forum, Sanofi, Nutricia, Probiodrug and EIP Pharma. All funding is paid to the institution.No other potential conflicts of interest relevant to this article exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}